Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $14.1700 (-7.08%) ($14.0300 - $15.4700) on Tue. Feb. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.13% (three month average) | RSI | 43 | Latest Price | $14.1700(-7.08%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.2% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(60%) IBB(59%) ARKK(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -2.565% in a week (0% probabilities). VIXM(-41%) VXX(-40%) TLT(-8%) UUP(-7%) IGOV(0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.565% (StdDev 5.13%) | Hourly BBV | 0 () | Intraday Trend | -7.9% | | | |
|
Resistance Level | $15.24 | 5 Day Moving Average | $15.37(-7.81%) | 10 Day Moving Average | $15.48(-8.46%) | 20 Day Moving Average | $15.24(-7.02%) | To recent high | -11.4% | To recent low | 99% | Market Cap | $1.795b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |